,,,here is a general question to the investing public,,,,,,,,,,,,,,,,,,what do you think happens if BoM fails to impress??......while we may still have possibly more favourable trials waiting for the green light to enter the clinic! ,,,, these secondary indications may be the pipeline that will stay the share price in the event we dont get the 100% on BoM,,,,, I certainly dont think we get a 0% and if we lay somewhere in the middle I think there will be enuff speculation that a respectable share price will be maintained in the course of this drug developement,,The CKD numbers for one thing seem to be of very great importance to all,,shareholders and patients alike.

Ideally ,,we want it all,,,,,Good BoM results and more detailed data to properly design the follow up trials!!